Live Breaking News & Updates on Dcgi

Stay informed with the latest breaking news from Dcgi on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Dcgi and stay connected to the pulse of your community

4 insights to kick-start your day, featuring India's problems with drugmakers

In Primeshots today: Drugmakers face regulatory heat; consensus at G20; PVR Inox shines; and Taiwan impact.

Japan , India , Drug-administration , Drug-controller-general , Pvr-inox , Taiwan , Dcgi , G20 , China ,

Sale Of False Version Of 2 Drugs To Be Monitored In India After WHO Alert

The Drugs Controller General of India has directed the drugs controllers of all states and Union territories to keep a strict vigil on the sale and distribution of falsified versions of two drugs.

India , Adcetris-brentuximab-vedotin , Gentium-srl , Defitelio-defibrotide , World-health-organisation , Takeda-pharmaceutical-company , Central-drugs-standard-control-organisation , Drugs-controller-general , Takeda-pharmaceutical-company-limited , Brentuximab-vedotin , United-nations , Cosmetics-act

dcgi: DCGI asks states to keep vigil on sale of falsified versions of 2 drugs following WHO alerts

The Drugs Controller General of India (DCGI) has issued an advisory to keep a strict watch on the sale and distribution of falsified versions of two drugs, Defitelio and Adcetris, following alerts from the World Health Organisation (WHO). The WHO has identified multiple falsified versions of Adcetris in circulation, and a falsified version of Defitelio has also been detected.

India , Kozhikode , Kerala , Defitelio-defibrotide , Adcetris-brentuximab-vedotin , Gentium-srl , Takeda-pharmaceutical-company , Offering-college , Indian-school-of-business , Healthcare-management-analytics-programme , World-health-organisation , Drugs-controller-general

DCGI asks states to keep vigil on sale of falsified versions of 2 drugs after WHO alerts

New Delhi, Sep 10 (PTI) The Drugs Controller General of India (DCGI) has directed the drugs controllers of all states and Union territories to keep a strict vigil on the sale and distribution of falsified versions of two drugs, liver medication Defitelio and Takeda's cancer drug Adcetris (injection), following alerts issued by the World Health Organisation (WHO).

Dcgi , Who , Who-alert-on-drugs , Healthcare , Healthcare-india , Health-news ,

dcgi: After crackdown on spurious medicines, India's drug regulator collating data of pharma plants

The companies have also been asked to share information on international approvals obtained from the European Union, US Food and Drug Administration, Japan's Pharmaceuticals and Medical Devices Agency, Brazilian Health Regulatory Agency (Anvisa), among other regulatory bodies abroad.

India , Japan , Gambia , New-delhi , Delhi , Kozhikode , Kerala , Devices-agency , Healthcare-management-analytics-programme , Brazilian-health-regulatory-agency-anvisa , European-union

Mint Explainer: The trigger behind DGCI alert on Abbott's Digene, Takeda's cancer jab

DCGI has issued advisories to discontinue the use of Abbott's Digene Gel, a popular antacid medication, and Takeda's Adcetris Injection for cancer treatment, citing safety concerns

India , Brentuximab-vedotin , India-central-drugs-standard-control-organization , World-health-organization , Digene-gel , Diegene-gel , Abbott-india , Adcetris-injection , Takeda-pharmaceutical , Central-drugs-standard-control-organization , Cosmetic-act , Dcgi

Abbott India Recalls Batches of Popular Antacid Digene Gel After Complaint of Foul Taste & Odour

The Mumbai-based company is voluntarily recalling batches, especially of the mint and orange-flavoured syrup. Also, the company has decided to voluntarily stop the production of all variants of Digene Gel manufactured at their Goa facility

India , Mumbai , Maharashtra , Rajeev-singh-raghuvanshi , Union-ministry-of-health , Union-territories , Abbott-india , Digene-gel , Drug-controller-general , Digene-gel-mint , Digene-mint , Union-ministry

Abbott India recalls antacid Digene Gel after DCGI advisory

State drugs controllers have been advised to keep strict vigil on the movement, sale and distribution and stock of the said products in the market, draw samples if the product is lying in the market, and initiate necessary action

India , Digene-gel , Cosmetic-act , Abbott , Abbott-india , Drugmaker , Recall , Digene-recall , Dcgi , Drug-controller-general-of-india , Advisory

DCGI issues advisory as US-based Abbott recalls batches of Digene gel

Abbott India Limited, through a letter dated August 18, intimated to DCGI regarding voluntary product recall of all batches of Digene Gel of all flavours (mint, orange, mix fruits flavour) which are within the shelf life and manufactured at Goa facility. "The impugned product may be unsafe and its use may result in adverse reaction," the DCGI letter dated August 31 said.

India , Kozhikode , Kerala , Indian-school-of-business , Abbott-india , Offering-college , Healthcare-management-analytics-programme , Drugs-controller-general , Digene-gel , Abbott-india-limited , Verna-industrial-estate

Abbott India recalls antacid Digene Gel, DCGI issues advisory

State drugs controllers have been advised to keep strict vigil on the movement, sale and distribution and stock of the said products in the market, draw samples if the product is lying in the market, and initiate necessary action

India , Digene-gel , Cosmetic-act , Abbott , Abbott-india , Drugmaker , Recall , Digene-recall , Dcgi , Drug-controller-general-of-india , Advisory